U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06811220) titled 'The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients' on Jan. 28.
Brief Summary: The aim of this study is evaluation of the potential neuroprotective effect of oral hesperidin and diosmin in reducing paclitaxel- induced peripheral neuropathy in the treatment of breast cancer patients.
Study Start Date: Jan. 27
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: Hespiridin and Diosmin
Daflon(R) (50 mg Hesperidin and Micronized purified flavonoid fraction (MPFF) 450 diosmin combination one film coated tablet)
Recruitment St...